Monday, October 05, 2015 2:16:57 PM
I really see a patent grant....or a potential partnership/Join Venture way ever before we see a prototype developed by HyperSolar themselves...
Results of Operations for the Year Ended June 30, 2015 compared to the Year Ended June 30, 2014.
Operating Expenses
Operating expenses consists primarily of research and development expenses and general and administrative expenses incurred in connection with the operation our business. For the year ended June 30, 2015 operating expenses were $542,404 and $558,669 for the prior period ended June 30, 2014. The net decrease of $16,265 in operating expenses consisted primarily of research and development costs in the amount of $15,628 together with professional fees in the amount of $34,524, offset against an increase in marketing expenses of $13,687, and an overall increase in other general and administrative expenses of $20,200. Marketing expenses consist of expenses incurred in connection with our public responses. Other general administrative expenses consist of health insurance expenses, rental expense and other office expenses.
Recent HYSR News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 09:31:40 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/02/2024 05:15:09 AM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 01/25/2024 09:40:59 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/24/2024 09:32:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 08:28:16 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2023 09:03:04 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/29/2023 08:33:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2023 08:13:34 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM